MedTrace Logo

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

NCT04756921 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-02-16

No results posted yet for this study

Summary

Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting response to treatment. This study aimed to evaluate the ability of pretreatment positron emission tomography/computed tomography (PET/CT) 18F-FDG-based heterogeneity to predict the response to pyrotinib in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).

Conditions

Interventions

DRUG

Pyrotinib

Pyrotinib 400mg po qd

Sponsors & Collaborators

  • Biyun Wang, MD

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2020-07-24
Completion
2020-07-24

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04756921 on ClinicalTrials.gov